Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids

被引：10

作者：

Jinno, Sadao ^{[1
]}

Akashi, Kengo ^{[1
]}

Onishi, Akira ^{[2
]}

Nose, Yoko ^{[1
]}

Yamashita, Mai ^{[1
]}

Saegusa, Jun ^{[1
]}

机构：

[1] Univ Grad Sch Med, Dept Rheumatol & Clin Immunol, 7-5-2 Kusunoki Chou, Kobe, Hyogo 6500017, Japan

[2] Kyoto Univ, Grad Sch Med, Dept Adv Med Rheumat Dis, Kyoto, Japan

来源：

RHEUMATOLOGY INTERNATIONAL | 2022年 / 42卷 / 08期

关键词：

Antifungal agents; therapeutic use; Atovaquone; pharmacology; Incidence; Pneumocystis pneumonia; prevention and control; Rheumatic diseases; drug therapy; Trimethoprim sulfamethoxazole drug combination; AEROSOLIZED PENTAMIDINE; JIROVECII PNEUMONIA; CARINII-PNEUMONIA; SUSPENSION; BLOOD;

D O I：

10.1007/s00296-021-04945-w

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We compared the prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) with atovaquone for pneumocystis pneumonia (PCP) in patients with connective tissue diseases (CTDs) receiving high-dose glucocorticoids. Patients with CTDs aged >= 18 years who were treated with a prolonged course (>= 4 weeks) of glucocorticoids (>= 20 mg/day prednisone) in a Japanese tertiary center between 2013 and 2017 were included. The patients were categorized into two groups: TMP-SMX and atovaquone group. Adjusted cumulative incidence of PCP was compared between the two groups after propensity score weighting for differences in confounding factors. A total of 480 patients with a prolonged high-dose glucocorticoid treatment were identified. Out of 383 patients with TMP-SMX prophylaxis, 102 (26.8%) patients experienced adverse events leading to discontinuation within 4 weeks of initiation, while no patient in the atovaquone discontinued the therapy. Two hundred eighty-one patients received TMP-SMX, while 107 received atovaquone for PCP prophylaxis. During a total of 397.0 person-years, 7 PCP cases (2 in the TMP-SMX, 5 in the atovaquone) occurred with a mortality rate of 54.5%. After adjusting for differences in baseline characteristics, the adjusted cumulative incidence of PCP was similar between the two group (HR 0.97, 95% CI 0.19-5.09, p = 0.97). Prophylactic effects for PCP in CTDs patients receiving prolonged high-dose glucocorticoids were similar between TMP-SMX and atovaquone. Atovaquone was well-tolerated with no side effects.

引用

页码：1403 / 1409

页数：7

共 18 条

[1] Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides [J].

Chan, C ;

Montaner, J ;

Lefebvre, EA ;

Morey, G ;

Dohn, M ;

McIvor, RA ;

Scott, J ;

Marina, R ;

Caldwell, P .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :369-376

[2] A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation [J].

Colby, C ;

McAfee, SL ;

Sackstein, R ;

Finkelstein, DM ;

Fishman, JA ;

Spitzer, TR .

BONE MARROW TRANSPLANTATION, 1999, 24 (08) :897-902

[3] Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement [J].

Freeman, CD ;

Klutman, NE ;

Lamp, KC ;

Dall, LH ;

Strayer, AH .

ANNALS OF PHARMACOTHERAPY, 1998, 32 (10) :1004-1007

[4] Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation [J].

Gabardi, Steven ;

Millen, Peter ;

Hurwitz, Shelley ;

Martin, Spencer ;

Roberts, Keri ;

Chandraker, Anil .

CLINICAL TRANSPLANTATION, 2012, 26 (03) :E184-E190

[5] Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease [J].

Kimura, Miho ;

Tanaka, Sumiaki ;

Ishikawa, Akira ;

Endo, Hirahito ;

Hirohata, Shunsei ;

Kondo, Hirobumi .

RHEUMATOLOGY INTERNATIONAL, 2008, 28 (07) :673-676

[6] Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases [J].

Kitazawa, Takatoshi ;

Seo, Kazunori ;

Yoshino, Yusuke ;

Asako, Kurumi ;

Kikuchi, Hirotoshi ;

Kono, Hajime ;

Ota, Yasuo .

JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (05) :351-354

[7] Pharmacokinetics and drug metabolism in the elderly [J].

Klotz, Ulrich .

DRUG METABOLISM REVIEWS, 2009, 41 (02) :67-76

[8] Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus [J].

Lertnawapan, Ratchaya ;

Totemchokchyakarn, Kitti ;

Nantiruj, Kanokrat ;

Janwityanujit, Suchela .

RHEUMATOLOGY INTERNATIONAL, 2009, 29 (05) :491-496

[9] An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients [J].

Limper, Andrew H. ;

Knox, Kenneth S. ;

Sarosi, George A. ;

Ampel, Neil M. ;

Bennett, John E. ;

Catanzaro, Antonino ;

Davies, Scott F. ;

Dismukes, William E. ;

Hage, Chadi A. ;

Marr, Kieren A. ;

Mody, Christopher H. ;

Perfect, John R. ;

Stevens, David A. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (01) :96-128

[10] Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids [J].

Park, Jun Won ;

Curtis, Jeffrey R. ;

Moon, Jinyoung ;

Song, Yeong Wook ;

Kim, Suhnggwon ;

Lee, Eun Bong .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (05) :644-649

← 1 2 →